Indantadol
Indantadol (CHF-3381, V-3381) is a drug which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.
primaryTopic
Indantadol
Indantadol (CHF-3381, V-3381) is a drug which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.
has abstract
Indantadol (CHF-3381, V-3381) ...... in phase IIb clinical trials.
@en
インダンタドール(Indantadol)は、Vernalis ...... 床での神経因性疼痛の治療に対する大きな効果は示されなかった。
@ja
ATC prefix
CAS number
202844-10-8
FDA UNII code
Z3867B9SQP
IUPAC name
N-(2,3-dihydro-1H-inden-2-yl)glycinamide
@en
thumbnail
Wikipage page ID
26,929,916
Wikipage revision ID
737,418,616
ChemSpiderID
16,017,060
legal status
molecular weight
routes of administration
smiles
NCCNC1Cc2ccccc2C1
subject
hypernym
comment
Indantadol (CHF-3381, V-3381) ...... in phase IIb clinical trials.
@en
インダンタドール(Indantadol)は、Vernalis ...... 床での神経因性疼痛の治療に対する大きな効果は示されなかった。
@ja
label
Indantadol
@en
インダンタドール
@ja